FIGS Stock Analysis: Figs | NYSE
Apparel Manufacturing | NYSE, USA | Market Cap: 1.654m USD | 12M Return: 76.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 36.9M
EPS Trend: -0.6%
Qual. Beats: 0
Rev. Trend: 85.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
FIGS, Inc. is a direct-to-consumer (DTC) healthcare apparel and lifestyle company headquartered in Santa Monica, California, operating in the United States and internationally through its subsidiary, FIGS Canada, Inc. Founded in 2013, the company designs and sells scrubwear alongside a growing range of non-scrubwear products, including outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and lifestyle items such as performance leggings, pima cotton tops, fleeces, and accessories like scrub caps, lanyards, and bags. FIGS markets primarily to healthcare professionals through its own digital platform-website and mobile app-as well as a B2B channel and physical retail stores.
Within the GICS Health Care Supplies sub-industry, FIGS occupies a niche focused on functional and lifestyle apparel for medical professionals rather than broader medical devices or consumables. Its asset-light DTC model allows the company to control brand presentation, pricing, and customer data by selling directly to consumers, bypassing traditional wholesale distributors that historically dominated the medical uniform market.
- Healthcare hiring slowdown pressures core scrubwear revenue growth
- International segment expansion offsets domestic demand softness
- Marketing and promotional spend weigh on operating margin outlook
| Net Income: 40.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -4.67 > 1.0 |
| NWC/Revenue: 52.84% < 20% (prev 53.24%; Δ -0.39% < -1%) |
| CFO/TA 0.09 > 3% & CFO 48.7m > Net Income 40.6m |
| Net Debt (-216.4m) to EBITDA (62.2m): -3.48 < 3 |
| Current Ratio: 5.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (196.1m) vs 12m ago 20.70% < -2% |
| Gross Margin: 66.10% > 18% (prev 67.35%; Δ -1.25% > 0.5%) |
| Asset Turnover: 122.7% > 50% (prev 107.4%; Δ 15.26% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 432.2m - Total Current Liabilities 80.2m) / Total Assets 563.4m |
| B: 0.19 (Retained Earnings 105.0m / Total Assets 563.4m) |
| C: 0.10 (EBIT TTM 51.8m / Avg Total Assets 542.9m) |
| D: 3.24 (Book Value of Equity 430.6m / Total Liabilities 132.8m) |
| Altman-Z'' = 8.75 = AAA |
| DSRI: 0.67 (Receivables 5.24m/6.55m, Revenue 666.1m/561.2m) |
| GMI: 1.02 (GM 67.35% / 66.10%) |
| AQI: 0.96 (AQ_t 0.07 / AQ_t-1 0.08) |
| SGI: 1.19 (Revenue 666.1m / 561.2m) |
| TATA: -0.01 (NI 40.6m - CFO 48.7m) / TA 563.4m) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 10.33 with a total of 2,741,107 shares traded. Over the past week, the price has changed by +2.79%, over one month by -11.41%, over three months by -28.66% and over the past year by +76.88%.
Current recommended Stop Loss: 9.50 (which is 8% or 1.3 ATR below the current price).
Figs has received a consensus analysts rating of 2.90. Therefore, it is recommended to hold FIGS.
- StrongBuy: 0
- Buy: 1
- Hold: 7
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 17.6 | 70.7% |
P/E Trailing = 45.0
P/E Forward = 39.2157
P/S = 2.4828
P/B = 3.8752
Revenue TTM = 666.1m USD
EBIT TTM = 51.8m USD
EBITDA TTM = 62.2m USD
Long Term Debt = 52.3m USD (estimated: total debt 60.6m - short term 8.27m)
Short Term Debt = 8.27m USD (from shortTermDebt, last quarter)
Debt = 60.6m USD (from shortLongTermDebtTotal, last quarter) (leases 60.6m already included)
Net Debt = -216.4m USD (calculated: Debt 60.6m - CCE 277.0m)
Enterprise Value = 1.44b USD (1.65b + Debt 60.6m - CCE 277.0m)
Interest Coverage Ratio = unknown (Ebit TTM 51.8m / Interest Expense TTM 0.0)
EV/FCF = 36.44x (Enterprise Value 1.44b / FCF TTM 39.4m)
FCF Yield = 2.74% (FCF TTM 39.4m / Enterprise Value 1.44b)
FCF Margin = 5.92% (FCF TTM 39.4m / Revenue TTM 666.1m)
Net Margin = 6.10% (Net Income TTM 40.6m / Revenue TTM 666.1m)
Gross Margin = 66.10% ((Revenue TTM 666.1m - Cost of Revenue TTM 225.8m) / Revenue TTM)
Gross Margin QoQ = 65.59% (prev 62.94%)
Tobins Q-Ratio = 2.55 (Enterprise Value 1.44b / Total Assets 563.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 60.6m)
Taxrate = 21.53% (11.1m / 51.8m)
NOPAT = 40.6m (EBIT 51.8m * (1 - 21.53%))
Current Ratio = 5.39 (Total Current Assets 432.2m / Total Current Liabilities 80.2m)
Debt / Equity = 0.14 (Debt 60.6m / totalStockholderEquity, last quarter 430.6m)
Debt / EBITDA = -3.48 (Net Debt -216.4m / EBITDA 62.2m)
Debt / FCF = -5.49 (Net Debt -216.4m / FCF TTM 39.4m)
Total Stockholder Equity = 419.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.49% (Net Income 40.6m / Total Assets 563.4m)
RoE = 9.69% (Net Income TTM 40.6m / Total Stockholder Equity 419.5m)
RoCE = 10.98% (EBIT 51.8m / Capital Employed (Equity 419.5m + L.T.Debt 52.3m))
RoIC = 8.87% (NOPAT 40.6m / Invested Capital 458.2m)
WACC = 8.28% (E(1.65b)/V(1.71b) * Re(8.58%) + D(60.6m)/V(1.71b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 15.56 | Cagr: 3.37%
[DCF] Terminal Value 73.10% ; FCFF base≈48.0m ; Y1≈42.1m ; Y5≈34.0m
[DCF] Fair Price = 4.80 (EV 546.4m - Net Debt -216.4m = Equity 762.8m / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -0.65 | EPS CAGR: -0.66% | SUE: 0.32 | # QB: 0
Revenue Correlation: 85.25 | Revenue CAGR: 6.52% | SUE: 0.55 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+0.00% | Revisions=+17% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=+0.00% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=0.27 | Chg30d=+0.00% | Revisions=+55% | GrowthEPS=+40.3% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=0.32 | Chg30d=+0.00% | Revisions=+42% | GrowthEPS=+20.5% | GrowthRev=+7.9%
[Analyst] Revisions Ratio: +42% (up=17, down=6)